When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …

Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …

Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …

Accurate risk stratification of gastrointestinal stromal tumors (GISTs) has become
increasingly important owing to emerging adjuvant systemic treatments. All GISTs have …

Purpose The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance)
study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib …

Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

Importance Little is known about whether the duration of adjuvant imatinib influences the
prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet …

Background The effect of imatinib discontinuation on progression-free survival and overall
survival in long-lasting responders with advanced gastrointestinal stromal tumours (GIST) is …

Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI
stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is …